CDXC News and Press, ChromaDex Corporation From 06/24/24

NR improved the six-minute walking distance and treadmill walking time for those with PAD ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research, shares results from a milestone phase II clinical study showcasing the promising effe...

Clinical study results demonstrated that Niagen IV had no adverse side effects, provided superior tolerability, and a 75% shorter infusion time, with blood NAD+ levels peaking sooner and higher three hours post-infusion as compared to NAD+ IV. The U.S. FDA authorized nicotinamide riboside...

2024-06-07 09:51:21 ET More on BioCardia, ChromaDex, etc. Charles River Laboratories: Fair Valuation Against Fundamentals BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss' BioCardia inte...

ChromaDex plans to conduct additional studies on NRC in anticipation of filing for an Investigational New Drug Application (IND) for the treatment of AT ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, ...

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presenta...

ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy-aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2024 Investor ...

Judges award Niagen for its “high-quality, unparalleled” healthy aging research ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, is proud to announce that its flagship ingredient, Niagen ...

2024-05-08 20:26:10 ET ChromaDex Corporation (CDXC) Q1 2024 Results Conference Call May 08, 2024 04:30 PM ET Company Participants Ben Shamsian - IR Rob Fried - CEO Brianna Gerber - CFO Andrew Shao - SVP, Scientific and Regulatory Affairs Conference Call...

2024-05-08 16:09:54 ET More on ChromaDex ChromaDex Corporation (CDXC) Q4 2023 Earnings Call Transcript ChromaDex Corporation 2023 Q4 - Results - Earnings Call Presentation ChromaDex Q1 2024 Earnings Preview ChromaDex GAAP EPS of $0.00 beats by $0.02, revenue ...

Total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three months ended March 31, 2024. Reiterated full year outlook including net sales growth of at least 16%. ChromaDex Corp. (NASDAQ:CDXC) today anno...